Thu Sep 26 13:00:04 UTC 2024: ## CRISPR Therapeutics Sees Mixed Investor Sentiment as XTX Topco Ltd Reduces Stake

**New York, NY -** CRISPR Therapeutics AG (NASDAQ:CRSP), a leading gene-editing company, has seen a mixed bag of investor activity in recent quarters. Notably, XTX Topco Ltd, an institutional investor, decreased its position in CRISPR Therapeutics by 28.7% in the second quarter, selling off 3,071 shares and leaving them with 7,620 shares valued at $412,000.

While XTX Topco Ltd reduced its stake, other institutional investors have shown increased interest in CRISPR Therapeutics. Global Trust Asset Management LLC, Larson Financial Group LLC, GPS Wealth Strategies Group LLC, Riggs Asset Management Co. Inc., and NBC Securities Inc. all boosted their holdings in the company during the past quarters.

Despite the varied investor activity, overall institutional ownership in CRISPR Therapeutics remains high at 69.20%.

CRISPR Therapeutics’ stock opened at $45.92 on Thursday, with a market cap of $3.91 billion. Analysts have issued a mixed bag of ratings, with three giving a “sell” rating, eight issuing “hold” ratings, and nine assigning “buy” ratings. The average rating is “Hold” with an average price target of $75.63.

CRISPR Therapeutics is focused on developing gene-based medicines for serious diseases using its CRISPR/Cas9 platform, a revolutionary gene-editing technology. The company has a diverse portfolio of programs in various areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

While investor sentiment surrounding CRISPR Therapeutics remains mixed, the company’s potential in the rapidly growing gene-editing field continues to attract attention from both institutional and individual investors.

Read More